Compare Johnson & Johnson (JNJ) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Johnson & Johnson trades at $250.38 (market cap $598.96B), while iShares 20 Plus Year Treasury Bond ETF trades at $83.67. The key difference: Johnson & Johnson pays a 2.15% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | TLT | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $92.06 |
52-Week Low | $164.36 | $83.02 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $83.89, down 0.75% on the day. Technical indicators signal a bearish trend with moving averages showing selling pressure, while oscillators are neutral. The ETF has faced significant outflows amid rising interest rate concerns, with recent articles highlighting competition from cash ETFs and corporate bond alternatives offering higher yields. Dividend payments remain consistent but modest.
The outlook for TLT hinges on Federal Reserve policy shifts; potential rate cuts could boost long-term bonds, but persistent inflation risks may extend volatility. Investors face duration risk and opportunity cost versus shorter-term instruments. Wall Street sentiment is mixed, with some seeing value at current yields after steep declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
